000 01330 a2200349 4500
005 20250516102324.0
264 0 _c20120924
008 201209s 0 0 eng d
022 _a1097-6744
024 7 _a10.1016/j.ahj.2012.04.011
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aWhite, William B
245 0 0 _aCardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.
_h[electronic resource]
260 _bAmerican heart journal
_cJul 2012
300 _a14-20 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650 0 4 _aAllopurinol
_xadverse effects
650 0 4 _aCardiovascular Diseases
_xcomplications
650 0 4 _aDouble-Blind Method
650 0 4 _aFebuxostat
650 0 4 _aGout
_xcomplications
650 0 4 _aGout Suppressants
_xadverse effects
650 0 4 _aHumans
650 0 4 _aProspective Studies
650 0 4 _aThiazoles
_xadverse effects
700 1 _aChohan, Saima
700 1 _aDabholkar, Aruna
700 1 _aHunt, Barbara
700 1 _aJackson, Robert
773 0 _tAmerican heart journal
_gvol. 164
_gno. 1
_gp. 14-20
856 4 0 _uhttps://doi.org/10.1016/j.ahj.2012.04.011
_zAvailable from publisher's website
999 _c21943661
_d21943661